A phase II, randomized, open-label, pilot study to evaluate the safety and the effects on bone resorption of saracatinib (AZD0530) in patients with prostate cancer or breast cancer with metastatic bone disease
Author:
Aklilu* M.,Hussain A.,Evans C.P.,Hannon R.A.,Lipton A.,Dimairo M.,Yu J.,Zobel P.,Torti F.M.,Finkelman R.D.
Subject
Histology,Physiology,Endocrinology, Diabetes and Metabolism
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Breast cancer bone metastases: pathogenesis and therapeutic targets;The International Journal of Biochemistry & Cell Biology;2018-03